Novo's NovoRapid Has 10-20 Min. Onset Of Action - EU Labeling
Executive Summary
Novo Nordisk's diabetes mellitus treatment insulin aspart has an onset of action time of 10 to 20 minutes, according to European draft labeling for the human insulin analogue.
You may also be interested in...
EMEA Clears Four Biologics In 1999 Before FDA, And Five Later Than FDA
The European Medicines Evaluation Agency approved four biological products in 1999 that have not yet been licensed by FDA.
EMEA Clears Four Biologics In 1999 Before FDA, And Five Later Than FDA
The European Medicines Evaluation Agency approved four biological products in 1999 that have not yet been licensed by FDA.
Novo Nordisk Demerger Expected To Aid External Collaborations
Novo expects the demerger of its healthcare and enzyme businesses in January 2001 to enhance possibilities for collaborations with other companies.